

November 10, 2025

Narayana Hrudayalaya Limited: Update on material event

Summary of ratings outstanding

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term - Term loans	1,714.00	1,714.00	[ICRA]AA (Stable); Outstanding
Short-term - Non-fund based	45.00	45.00	[ICRA]A1+; Outstanding
Long-term/ Short-term - Unallocated	1,956.00	1,956.00	[ICRA]AA (Stable)/ [ICRA]A1+; Outstanding
Long-term/ Short-term - Working capital	80.00	80.00	[ICRA]AA (Stable)/ [ICRA]A1+; Outstanding
Non-fund based - Working capital (sublimit)#	(90.00)	(90.00)	[ICRA]AA (Stable)/ [ICRA]A1+; Outstanding
Long-term – Fund based CC	100.00	100.00	[ICRA]AA (Stable); Outstanding
Non-convertible debenture	300.00	300.00	[ICRA]AA (Stable); Outstanding
Non-convertible debenture	1,000.00	1,000.00	[ICRA]AA (Stable); Outstanding
Total	5,195.00	5,195.00	

*Instrument details are provided in Annexure-I

Rationale

Material event

On October 30, 2025, Narayana Hrudayalaya Limited (NHL/the company) released a disclosure to the stock exchanges stating that the company (through its step subsidiary in the UK) has entered into an agreement with Bridgepoint Group to acquire 100% (60,001 shares) shareholding in Practice Plus Group Hospitals Limited (PPGHL), a company incorporated and based out of the United Kingdom. The transaction was subsequently completed on November 06, 2025. The shares were acquired by Narayana Hrudayalaya UK Ltd. (NHUK), wholly owned subsidiary of Health City Cayman Islands Limited (HCCI) which in turn is a wholly owned subsidiary of NHL. PPGHL is an independent healthcare provider in the United Kingdom, focused on secondary care with committed National Health Service (NHS) contracts. PPGHL operates ten hospitals/surgical centers, two urgent treatment centers/diagnostic centers, and one ophthalmology center with a total bed capacity of 330 beds. For PPGHL, NHS patients currently account for around 99% of the total patient volume and 93% of the total revenues with private pay patients (Self Pay + Insurance) accounting for the balance. The total consideration payable towards the acquisition is GBP 188.78 million (around Rs.2200 crore).

Impact of the material event

The acquisition is intended to build upon NHL's international presence after its expansion into Cayman Islands and is expected to result in relatively higher geographical diversity for NHL. The transaction is expected to be funded through a mix of HCCI's existing cash balances and incremental debt which will be drawn down by NHUK / PPGHL. ICRA believes that the acquisition is unlikely to have any adverse material impact on NHL's credit profile. That said, following the transaction, ICRA expects NHL's peak Net Debt/OPBDITA to reach 2.1-2.3x as on March 31, 2026, given that NHL would be consolidating only part profits of PPGHL for the fiscal while the entire debt will be drawn down in November 2025. However, with full consolidation from FY2027, NHL's Net Debt/OPBDITA is expected to improve to 1.4-1.6x as on March 31, 2027 and improve further from thereon. ICRA continues to also draw comfort from NHL's overall healthy liquidity position and expected robust cash flow generation. Nonetheless, NHL's ability to achieve the desired scale-up in the non-NHS operations and profitability of PPGHL over the medium term will remain a key monitorable.

Please refer to the following link for the previous detailed rationale that captures the key rating drivers and their descriptions, liquidity position, rating sensitivities, Environmental and social risks and key financial indicators: [Click here](#)

Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Hospitals
Parent/Group support	Not Applicable
Consolidation/Standalone	For arriving at the ratings, ICRA has considered the consolidated financials of NHL along with its operational subsidiaries and associate companies (mentioned in Annexure-2) on account of the strong business and financial linkages among these entities.

About the company

NHL operates a chain of multispecialty, tertiary and primary healthcare facilities. Dr. Devi Shetty, who has over 30 years of medical experience, incorporated NHL in 2000. The Group, which initially focused on cardiac and renal sciences, expanded to additional areas of focus such as cancer care, neurology, neurosurgery, orthopedics, and gastroenterology and was rebranded as 'Narayana Health' in 2013 to reflect the diversified presence. The Group owns and operates certain hospitals and enters into management agreements with hospitals under which the Group acquires operating control. As on June 30, 2025, it had 40 healthcare facilities (5,563 operational beds) of which 18 hospitals (5,262 beds) are owned/operated, two (128 beds) are heart centres, 18 (no beds) are primary healthcare facilities including clinics and dialysis centre and two (169 beds) hospitals are in the Cayman Islands. NHL has a strong presence in Karnataka and eastern India, with an emerging presence in western, central and northern India. The Narayana Health brand is associated with the delivery of affordable healthcare services by leveraging its economies of scale.

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Current rating (FY2026)			Chronology of rating history for the past 3 years					
	FY2026			FY2025		FY2024		FY2023	
	Type	Amount rated (Rs crore)	Nov 10, 2025	Date	Rating	Date	Rating	Date	Rating
Fund Based-Cash Credit	Long Term	100	[ICRA]AA (Stable)	Jan 20, 2025	[ICRA]AA (Stable)	Feb 02, 2024	[ICRA]AA (Stable)	Apr 25, 2022	[ICRA]AA- (Positive)
				-	-	-	-	Mar 06, 2023	[ICRA]AA (Stable)
Fund Based/ Non-Fund Based- Others	Long Term/ Short Term	80	[ICRA]AA (Stable)/ [ICRA]A1+	Jan 20, 2025	[ICRA]AA (Stable)/ [ICRA]A1+	Feb 02, 2024	[ICRA]AA (Stable)/ [ICRA]A1+	Apr 25, 2022	[ICRA]AA- (Positive)/ [ICRA]A1+
				-	-	-	-	Mar 06, 2023	[ICRA]AA (Stable)/ [ICRA]A1+
Interchangeable- Others	Long Term/ Short Term	(90)	[ICRA]AA (Stable)/ [ICRA]A1+	Jan 20, 2025	[ICRA]AA (Stable)/ [ICRA]A1+	Feb 02, 2024	[ICRA]AA (Stable)/ [ICRA]A1+	Apr 25, 2022	[ICRA]AA- (Positive)/ [ICRA]A1+
				-	-	-	-	Mar 06, 2023	[ICRA]AA (Stable)/ [ICRA]A1+
Unallocated- Unallocated	Long Term/Short Term	1,956.00	[ICRA]AA (Stable)/ [ICRA]A1+	Jan 20, 2025	[ICRA]AA (Stable)/ [ICRA]A1+	Feb 02, 2024	[ICRA]AA (Stable)/ [ICRA]A1+	Apr 25, 2022	[ICRA]AA- (Positive)/ [ICRA]A1+
				-	-	-	-	Mar 06, 2023	[ICRA]AA (Stable)/ [ICRA]A1+
Fund Based-Term Loan	Long Term	1,714.00	[ICRA]AA (Stable)	Jan 20, 2025	[ICRA]AA (Stable)	Feb 02, 2024	[ICRA]AA (Stable)	Apr 25, 2022	[ICRA]AA- (Positive)
				-	-	-	-	Mar 06, 2023	[ICRA]AA (Stable)
Non-Fund Based- Others	Short Term	45	[ICRA]A1+	Jan 20, 2025	[ICRA]A1+	Feb 02, 2024	[ICRA]A1+	Apr 25, 2022	[ICRA]A1+
				-	-	-	-	Mar 06, 2023	[ICRA]A1+
NCD	Long Term	300	[ICRA]AA (Stable)	Jan 20, 2025	[ICRA]AA (Stable)	Feb 02, 2024	[ICRA]AA (Stable)	-	-
NCD	Long Term	1,000.00	[ICRA]AA (Stable)	Jan 20, 2025	[ICRA]AA (Stable)	-	-	-	-

Complexity level of the rated instrument

Instrument	Complexity Indicator
Long term- Term loan	Simple
Short term- Non-fund Based	Very Simple
Long term/ Short term- Unallocated	NA
Long term/ Short term- Working capital	Simple
Non-Fund based- Working capital (sublimit)	Very Simple
Long term – Fund based CC	Simple
Non-convertible debenture	Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure-I: Instrument details

ISIN	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Long Term- Term Loan	FY2018	NA	FY2029	1,714.00	[ICRA]AA (Stable)
NA	Short Term- Non-fund Based	NA	NA	NA	45.00	[ICRA]A1+
NA	Long Term/ Short Term Unallocated	NA	NA	NA	1,956.00	[ICRA]AA (Stable)/ [ICRA]A1+
NA	Long Term/ Short Term Working Capital	NA	NA	NA	80.00	[ICRA]AA (Stable)/ [ICRA]A1+
NA	Non-Fund Based- Working Capital (sublimit)	NA	NA	NA	(90.00)	[ICRA]AA (Stable)/ [ICRA]A1+
NA	Fund based - Cash Credit	NA	NA	NA	100.00	[ICRA]AA (Stable)
INE410P08016	Non-convertible debenture	Mar-19-2024	8.25%	Mar-19-2029	300.00	[ICRA]AA (Stable)
Yet to be placed	Non-convertible debenture	NA	NA	NA	1,000.00	[ICRA]AA (Stable)

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure-II: List of entities considered for consolidated analysis

Company Name	NHL Ownership	Consolidation Approach
Narayana Hrudayalaya Surgical Hospital Pvt Ltd	100%	Full Consolidation
Meridian Medical Research and Hospital Ltd	99.13%	Full Consolidation
Narayana Hospitals Pvt Ltd	100%	Full Consolidation
Narayana Vaishno Devi Speciality Hospitals Pvt Ltd	100%	Full Consolidation
NH Integrated Care Private Limited	100%	Full Consolidation
Athma Healthtech Private Limited	100%	Full Consolidation
Health City Cayman Islands Ltd (HCCI)	100%	Full Consolidation
ENT in Cayman Ltd.	100%	Full Consolidation
Cayman Integrated Healthcare Limited	100%	Full Consolidation
NH Health Bangladesh private Limited	100%	Full Consolidation
Narayana Holdings Private Limited	100%	Full Consolidation
Narayana Health North America LLC	100%	Full Consolidation
Reya health Inc (formerly Cura Technologies Inc.)	43.58%	Full Consolidation
Medha AI Private Limited	100%	Full Consolidation
Narayana health Insurance Limited (NHIL)	100%	Full Consolidation
Samyat Healthcare Private Limited (SHPL)	100%	Full Consolidation
ISO Healthcare	0.00%	Full Consolidation

Source: Company data; As on March 31, 2024

ANALYST CONTACTS

Jitin Makkar

+91 124 4545 368

jitinm@icraindia.com

Kinjal Shah

+91 22 6114 3442

kinjal.shah@icraindia.com

Mythri Macherla

+91 22 6114 3435

mythri.macherla@icraindia.com

Tanvir Singh

+91 7009417559

tanvir.singh@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2025 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.